The Impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients
EASL LiverTree™, Freya Wellhöner, 207346
Paradoxically functioning onco-miR-155 and the tumor suppressor miR-194 consensus on PD-L1 immune checkpoint upregulation via MALAT-1 and XIST in hepatocellular carcinoma 
EASL LiverTree™, Sara Atwa, 207347
Upregulation of miR-34c driven by JNK and FOXO3 in livers expressing mutant Z alpha1-antitrypsin
EASL LiverTree™, Pasquale Piccolo, 207362
Refinement of diagnostic criteria and frequency estimation of LPAC syndrome: a French multicenter study
EASL LiverTree™, Dong Catherine, 207363
Role of alpha-1 antitrypsin genotypes in the progression of adult liver disease
EASL LiverTree™, Vítor Magno Pereira, 207364
Genetic ablation of CHOP decreases hepatic accumulation of mutant Z alpha1-antitrypsin
EASL LiverTree™, Sergio Attanasio, 207365
High caloric nutrition promotes hepatocellular damage and steatohepatitis in Wilson disease rats via amplified mitochondrial damage.
EASL LiverTree™, Claudia Einer, 207379
Mild iron overload in homozygous carriers of the alpha1-antitrypsin PiZ variant is not a major driver of liver fibrogenesis
EASL LiverTree™, Nurdan Guldiken, 207381
Reliability criteria for liver stiffness measurement with ARFI
EASL LiverTree™, Jérôme Boursier, 207398
The ProC3 marker of type III collagen formation accurately reflects hepatic inflammation and fibrosis stage in asymptomatic alcoholic liver disease patients
EASL LiverTree™, Maja Thiele, 207399
Liver stiffness measurement predicts short-term liver related-morbidity of allogeneic hematopoietic stem cell transplantation
EASL LiverTree™, Thomas Karlas, 207401
Liver stiffness measurement by 2D SWE from General Electric is similar with Transient Elastography in clinical significant portal hypertension diagnosis
EASL LiverTree™, Corina Rusu, 207402
Comparison of T2* and Signal Intensity Ratio Methods for MRI Assessment of Hepatic Iron Overload
EASL LiverTree™, Christopher Kagay, 207418
Serum biomarker usein decentralized care sites to overcome liver assessment barriers in patientswith chronic hepatitis C and HIV co-infection
EASL LiverTree™, anne loarec, 207419
Normal liver elasticity values in a healthy population, by age and gender, for two novel elastography systems
EASL LiverTree™, Anesa Mulabecirovic, 207420
IsFood-intake a Confusing Factor For Liver Stiffness Evaluation by2D-SWE in Normal Subjects?
EASL LiverTree™, Alina Popescu, 207436
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients
EASL LiverTree™, Elton Dajti, 207437
An effective defatting cocktail to reduce liver graft steatosis before transplantation
EASL LiverTree™, Lynda Aoudjehane, 207440
A merged protocol of hypothermic oxygenated machine perfusion and normothermic machine perfusion optimises the reconditioning of marginal donor livers
EASL LiverTree™, Yuri Boteon, 207441
Hepatocyte c-Jun N-terminal kinases determine cell fate and carcinogenesis in NEMO-deficient mice
EASL LiverTree™, Mohamed Ramadan Mohamed, 207455
Chemokine receptor CXCR3 modulates polarization of tumor associated macrophages limiting tumor growth and angiogenesis in murine hepatocellular carcinoma
EASL LiverTree™, Elisa Fabiana Brandt, 207456
Hepatocyte-derived Osteopontin drives the development of hepatocellular carcinoma
EASL LiverTree™, Romain Desert, 207457
AAV2 viral infection in liver and tumor development
EASL LiverTree™, Tiziana La Bella, 207458
Activated platelets contribute to the progression of hepatocellular carcinoma by altering the immune cell environment
EASL LiverTree™, Natasa Pavlovic, 207474
Tumor-stroma crosstalk enhances Reg3A expressions that drives the progression of hepatocellular carcinoma 
EASL LiverTree™, Yuri Cho, 207476
Canonical inhibition of TransformingGrowth Factor β Receptor 1 triggers proliferation of hepatocellular carcinoma andis associated with Toll Like Receptor 7 upregulation.
EASL LiverTree™, Fatma Mohamed, 207492
 S100a11 is part of a whole network of tumor suppressors and oncogenes deregulatedearly with hepatic steatosis and contributing to hepatocellular carcinoma development
EASL LiverTree™, Cyril Sobolewski, 207493
Low density neutrophils, as immunosuppressant, increased in HCC patients, highly correlated with advanced stage, predicted stage I HCC recurrence and all patients survival
EASL LiverTree™, Chien-Hao Huang, 207494
Chemosensitizing effects of beta-caryophyllene oxide in liver cancer
EASL LiverTree™, Silvia Di Giacomo, 207495
New targets for hepatocellular carcinoma therapy: the Myc/PRMT5/RNAP II circuit
EASL LiverTree™, Cristiana Porcu, 207510
Novel microRNA-based drug CD5-2 reduces liver cancer development in multi-drug-resistance gene-2 knockout mice
EASL LiverTree™, Ken Liu, 207511
KRAS-dependent AKT signaling drives hepatocyte proliferation to promote tumor development in a genetic model of liver cancer
EASL LiverTree™, Thomas Rösner, 207512
The impact of the epigenetic writer LSD1in the cell cycle control in liver fibrosis and hepatocellular carcinoma
EASL LiverTree™, Lingyu Wang, 207513
Longitudinal outcomes of the application of non-selective beta-blockers in portal hypertension: Are low-dose non-selective beta-blockers effective?
EASL LiverTree™, Seong Hee Kang, 207528
Sub maximally dilated Viatorr CX improves one year survival compared to conventional covered TIPS: a case-control study
EASL LiverTree™, Michael Praktiknjo, 207529
Prognosis after abdominal surgery in patients with idiopathic non-cirrhotic portal hypertension: a multicenter retrospective study
EASL LiverTree™, Laure ELKRIEF, 207530
High-dose but not low-dose enoxaparin substantially improves survival in cirrhotic patients with portal vein thrombosis
EASL LiverTree™, Laura Turco, 207544
Higher in-hospital and post-discharge mortality and hospital charges in cirrhotic patients with acute respiratory illness in the United States
EASL LiverTree™, Pauline Nguyen, 207545
Sepsis in HBV associated decompensated cirrhosis: A comparison between SIRS (Sepsis-1) and qSOFA (Sepsis-3) based criteria
EASL LiverTree™, Zhujun Cao, 207546
Assessment of portal hypertension evolution in HCV cirrhosis patients with baseline large oesophageal varices after sustained virological response
EASL LiverTree™, Marta Abadía, 207547
Characteristics of bone marrow drived mesenchymal stem cells in patients with liver cirrhosis
EASL LiverTree™, Ki Tae Suk, 207560
Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in cirrhosis: a systematic review and meta-analysis of randomized controlled trials
EASL LiverTree™, Roger F. Butterworth, 207561
Deleterious effect of proton pump inhibitors on the disease course of cirrhosis
EASL LiverTree™, Zsuzsanna Vitális, 207562
The impact of pulmonary arterial hypertension therapy in patients with portopulmonary hypertension: a single tertiary center cohort analysis
EASL LiverTree™, Frederik Nevens, 207563
Functional polymorphisms of innate immunity receptors are not risk factors for non-SBP type bacterial infections in cirrhosis
EASL LiverTree™, Tamas Tornai, 207578
The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis
EASL LiverTree™, Ji Jade King, 207579
MELD-score underestimates mortality in patients with nosocomial spontaneous bacterial peritonitis
EASL LiverTree™, Markus Kimmann, 207580
Development and predictive validity of the Cirrhosis-associated Ascites Symptom Scale: A cohort study of 103 patients.
EASL LiverTree™, Agnete Riedel, 207583
Hemodynamic disturbances across different stages of decompensated cirrhosis and influencie on outcomes
EASL LiverTree™, Marta García Guix, 207597
Improving assessment of hepatic encephalopathy in outpatient clinics 
EASL LiverTree™, Siddharth Sood, 207599
PROTON PUMP INHIBITORS INCREASE THE RISK OF MINIMAL AND OVERT HEPATIC ENCEPHALOPATHY AND THEY ARE ASSOCIATED WITH HIGH MORTALITY IN CIRRHOTIC PATIENTS.
EASL LiverTree™, Silvia Nardelli, 207600
Is obesity an additional negative factor in sarcopenic cirrhotic patients?
EASL LiverTree™, Daria D'Ambrosio, 207614
Liver cirrhosis and wound healing: Activation of von Willebrand factor and platelets
EASL LiverTree™, Lasse Langholm, 207615
The incidence of ulcer bleeding post endoscopic band ligation of esophageal varices
EASL LiverTree™, Salvador Machlab, 207616
Association between hospital type and transplant-free survival in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunts (TIPS): A population-based study.
EASL LiverTree™, Jeffrey Mah, 207617
The Indication, Dosage and Duration of Proton Pump Inhibitors in Liver Cirrhosis 
EASL LiverTree™, Marianne De Roza, 207631
the effect of new infection control measures for the prevention of hospital acquired infections in cirrhotic patients
EASL LiverTree™, Vincenza Di Gregorio, 207632
Presepsin, C reactive protein and procalcitonin have similar accuracy for bacterial infection and sepsis in decompensated cirrhosis 
EASL LiverTree™, Petra Fischer, 207633
Predictive factors of esophageal varices recurrence after prophylactic endoscopic band ligation
EASL LiverTree™, Jaime Rodrigues, 207634
The role of hepatitis E in acute non-traumatic neuropathy in China: a prospective case-control study
EASL LiverTree™, Yijin Wang, 207650
Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe
EASL LiverTree™, Hartl Johannes, 207651
Dynamics of HBsAg clearance in a UK cohort of chronic HBV infection
EASL LiverTree™, Anna McNaughton, 207652
Expanding the donor pool- decontamination of HCV RNA positive kidneys with methylene blue
EASL LiverTree™, Sandra Ciesek, 207668
A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro
EASL LiverTree™, Lorenzo Piermatteo, 207670
Antiviral properties and liver specific delivery of a TLR1/2 ligand in HBV-infected in vitro and in vivo models
EASL LiverTree™, Julie Lucifora, 207685
Inhibition of Hepatitis Virus X protein (HBx) in HBV-Infected Primary Human Hepatocytes leads to the Reappearance of the Smc5/6 Complex
EASL LiverTree™, Rudolf Beran, 207686
FXR is a proviral factor whose binding to HBV genome is modulated by FXR agonist and correlates with presence of the activated chromatin mark H3K4me3 in an HBx dependant manner
EASL LiverTree™, Benoît Lacombe, 207687
Developing a new world monkey model of chronic HBV infection in the post-chimpanzee era
EASL LiverTree™, Christian Voitenleitner, 207688
FXR agonist GW4064 represses HBV replication in adult but not in young C3H/HeN mice after HBV transduction with rAAV2/8-HBV
EASL LiverTree™, Patrice André, 207702
Cellular RetinoicAcid-Binding Proteins Regulation of Hepatitis C Virus Infection
EASL LiverTree™, Takeshi Saito, 207703
Sodium taurocholate cotransporting popypeptide (NTCP) variants modulate HDV entry according to their function as a bile acid transporter but do not influence the antiviral effect of Myrcludex-B
EASL LiverTree™, Olympia Anastasiou, 207705
The correlations between HBV markers in sera and HBVcccDNA for genotypes
EASL LiverTree™, Takeshi Matsui, 207720
Estrogen receptor R1 and CAD are host factors for HDV replication and antiviral targets
EASL LiverTree™, Eloi VERRIER, 207721
Defining hos DNA repair factors in the formation of the hepatitis B virus covalentrly close circular DNA persistence reservoir 
EASL LiverTree™, Eloi VERRIER, 207722
Depletion of RIPK1 in hepatocytes exacerbates PolyI:C and Murine Hepatitis Virus induced liver damage
EASL LiverTree™, Michel Samson, 207724
Normalization of NK cell phenotype is delayed after successful interferon-free therapy in cirrhotic patients with chronic HCV infection. 
EASL LiverTree™, Elena Perpinan Mas, 207738
Transcriptome profiling of hepatitis B virus-infected human hepatocyte derived from chimeric mice with humanized liver
EASL LiverTree™, Shingo Nakamoto, 207739
Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort
EASL LiverTree™, Kristopher Bennett, 207742
Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis
EASL LiverTree™, Astrid Marot, 207757
Prevalence of alcoholic steatosis in the general adult Portuguese population
EASL LiverTree™, Jorge Leitao, 207759
Making sense of Liver Function tests: Is the Intelligent Liver Function Test (iLFT) cost-effective?
EASL LiverTree™, kathleen Boyd, 207760
Higher Early Post-Liver Transplant Mortality in Recipients with Severe Alcoholic Hepatitis Versus Alcoholic Cirrhosis
EASL LiverTree™, Brian Lee, 207762
The correlation of obesity with morbidity and mortality in alcoholic hepatitis. 
EASL LiverTree™, yasir yasiralazzawi, 207774
Serum metabolic profiling for the identification of patients with severe alcoholic hepatitis
EASL LiverTree™, Adelina Horhat, 207775
Corticosteroid treatment is associated with a resolution of altered CD4+ T cell phenotype in patients with severe alcoholic hepatitis
EASL LiverTree™, Ashwin Dhanda, 207777
Masked hemolysis as novel factor contributing to hepatic iron overload in ALD
EASL LiverTree™, Vanessa Rausch, 207779
Use of rifaximin in alcoholic hepatitis: Pilot study.
EASL LiverTree™, CESAR JIMENEZ, 207780
Increasing Trend forHepatocellular Carcinoma (HCC) Linked to Nonalcoholic Fatty Liver Disease(NAFLD) in the United States
EASL LiverTree™, Ethan Miller, 207792
Non-alcoholic fatty liver disease in non-obese young adults
EASL LiverTree™, Yaakov Maor, 207793
Risk factors for development of severe liver disease in more than 400 000 patients with type 2 diabetes: a population-based cohort study
EASL LiverTree™, Karl Björkström, 207794
Long-term Associations between Non-High Density Lipoprotein Cholesterol and Apolipoprotein B in Young Adulthood and Subclinical Atherosclerosis in Persons with Nonalcoholic Fatty Liver Disease in Middle Age: The CARDIA Study 
EASL LiverTree™, Lisa VanWagner, 207796
Plasma cells in non-alcoholic steatohepatitis correlates with disease activity
EASL LiverTree™, Mehul Lamba, 207810
Cardiovascular risk factors and fibrosisseverity in NAFLD: is there a link?
EASL LiverTree™, Davide Roccarina, 207811
Prevalence, severity and patterns of clinicalpractice in outpatient visits for suspected NAFLD - the German CONSTANS STUDY
EASL LiverTree™, Jörn Schattenberg, 207812
Analyze of ballooning biomarker in patients with non-alcoholic steatohepatitis: A multicenter study.
EASL LiverTree™, Yuji Ogawa, 207813
Health-related quality of life correlates with histological severity in non-alcoholic fatty liver disease
EASL LiverTree™, Yvonne Huber, 207814
Non-alcoholic fatty liver disease is omega-6 fatty acids diet dipendent in a group of obese children
EASL LiverTree™, Anna Mantovani, 207826
Change of microbiota in patients with improved fatty liver and obesity
EASL LiverTree™, Sang Bong Ahn, 207828
Role of L-carnitine in pathogenesis of the atherogenic dyslipidemia in ischemic heart disease with concominent nonalcoholic steatohepatitis
EASL LiverTree™, Igor Skrypnyk, 207829
Assessment of Baseline Hepatitis B Virus (HBV) Immunity and HBV Vaccine Responses in Prospectively Vaccinated Adults with Non Alcoholic Fatty Liver Disease (NAFLD)
EASL LiverTree™, Carla Coffin, 207830

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings